Skip to main content
GLAXO · Health Care · 2026-08-07

GlaxoSmithKline Pharmaceuticals Ltd

Stage 1 · wk 2In scan: Breakout WatchMARKET: BULL TOPPING · 2026-08-07
₹2,599.7
+0.78% today
₹44,040 Cr · Large cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and Trelegy Ellipta for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, an oral antibiotic to treat bacterial infections; CobadexCZS to treat mineral and vitamins deficiency states; Flutivate, a skin cream for adults, children, and infants; Tenovate to treat inflammatory and pruritic manifestations of steroid responsive dermatosis; CALPOL to treat mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment of specific bacterial skin infections; BETNOVATE for skin conditions; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin associated with redness and itch. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. The company was incorporated in 1924 and is based in Mumbai, India. GlaxoSmithKline Pharmaceuticals Limited operates as a subsidiary of GSK plc.

Visit company website →
P/E (TTM)
38.3
Forward 29.7
Earnings Growth (YoY)
+5.7%
Revenue +2.1%
ROE
+49.1%
Profit margin +27.1%
Dividend Yield
2.50%
P/B 22.8
vs 52W High
-17.8%
₹2,103.2 lo₹3,162.6 hi
17.8% below 52W high — deeper pullback
Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.
Stage Maturity
Week 2
1w13w26w
Week 2 — early base, needs time
How long this stock has been basing. Longer bases can produce stronger breakouts — but don't anticipate, wait for the breakout.
vs 200 DMA
5.8%
200 DMA: ₹2,456.9 · sloping down
Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.
Rel Volume
0.32x
vs 50-day avg
Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.
Trend Health
MA20 trending up · +4.0% vs MA50 +3.0%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
51.6%
20d Δ
+1.6pp
1M return
+3.1%
3M return
+11.6%
Sector Stage-2 % · last 20 days
Sector has 79 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
→ Flat
Stage 2%
50.5%
20d Δ
+0.5pp
1M return
+1.9%
3M return
+11.7%
Industry Stage-2 % · last 20 days
Industry has 53 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-15 → 2026-08-07
S2 40w
S2 21w
S2 17w
S4 19w
S4 17w
2023-05-152026-08-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 3w → S1 4w → S2 40w → S3 8w → S2 21w → S3 9w → S4 9w → S1 6w → S2 17w → S3 10w → S4 19w → S1 4w → S4 17w → S1 2w current
Total tracked: 167 weeks across 14 stage runs.
1M
+6.5%
3M
+5.0%
6M
+8.0%
YTD
+4.9%
1Y
-18.7%
Scan Membership
Breakout Watch
Latest: 2025-04-16
2 appearances in last 60 days. First seen: 2024-05-29.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-07S1
Wk 2 · Vol x
2026-08-06S1
Wk 2 · Vol x
2026-08-05S1
Wk 2 · Vol x
2026-08-04S1
Wk 2 · Vol x
2026-08-03S1
Wk 2 · Vol x
2026-07-31S1
Wk 1 · Vol x
2026-07-30S1
Wk 1 · Vol x
2026-07-29S1
Wk 1 · Vol x
2026-07-28S1
Wk 1 · Vol x
2026-07-27S14→1
Wk 1 · Vol x
2026-07-24S4
Wk 16 · Vol x
2026-07-23S4
Wk 16 · Vol x
Sector Peers — Stage 2All →
DIVISLAB
wk 12 · -3.6% from hi
8.5
LAURUSLABS
wk 16 · -0.3% from hi
8.4
PPLPHARMA
wk 4 · 0.0% from hi
8.2
LALPATHLAB
wk 9 · 0.0% from hi
7.9
SHILPAMED
wk 13 · 0.0% from hi
7.8
Moving averages & range
50 DMA
₹2,393.8
200 DMA
₹2,456.9
52W High
₹3,162.6
52W Low
₹2,103.2
5D Low
₹2,569.7
Resistance levels (recent highs)
20d High
₹2,662.3
60d High
₹2,662.3
120d High
₹2,699.3
250d High
₹2,869
Next resistance
+2.4%
to 20d High

All analytics based on EOD data. Data as of 2026-08-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.